Phase II clinical trials have been published to date as the CAVE mCRC trial, in which rechallenge strategy in refractory patients with RAS WT mCRC with cetuximab plus avelumab, an anti-programmed death ligand 1 (PD-L1) monoclonal antibody has demonstrated clinical evidence of improved overall survival, with the highest benefit obtained in those patients with baseline RAS/BRAF/EGFR WT circulating tumor DNA (ctDNA) (14). This evidence concerns the gene EGFR and neoplasm.